These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 22144665)
21. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726 [TBL] [Abstract][Full Text] [Related]
22. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650 [TBL] [Abstract][Full Text] [Related]
27. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839 [TBL] [Abstract][Full Text] [Related]
28. Recent updates on the development of ganetespib as a Hsp90 inhibitor. Choi HK; Lee K Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626 [TBL] [Abstract][Full Text] [Related]
29. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218 [TBL] [Abstract][Full Text] [Related]
30. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505 [TBL] [Abstract][Full Text] [Related]
31. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741 [TBL] [Abstract][Full Text] [Related]
32. Potent triazolothione inhibitor of heat-shock protein-90. Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743 [TBL] [Abstract][Full Text] [Related]
33. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Stravopodis DJ; Margaritis LH; Voutsinas GE Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746 [TBL] [Abstract][Full Text] [Related]
34. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314 [TBL] [Abstract][Full Text] [Related]
35. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Li Y; Zhang T; Schwartz SJ; Sun D Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325 [TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells. Shiraishi N; Onda T; Hayashi K; Onidani K; Watanabe K; Sekikawa S; Shibahara T Oncol Rep; 2021 Feb; 45(2):448-458. PubMed ID: 33416122 [TBL] [Abstract][Full Text] [Related]
37. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974 [TBL] [Abstract][Full Text] [Related]
39. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781 [TBL] [Abstract][Full Text] [Related]
40. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]